0 of 10 questions completed
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
0 of 10 questions answered correctly
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
You must score 0% to continue. Please click the link below to re-take the quiz
1. In aGVHD, it is thought that host antigen presenting cells:
2. In cGVHD dominant B-cell pathophysiology presents because organ damage is caused primarily by:
3. The two most commonly used GVHD severity grading systems for aGVHD divide severity assessments into mild, moderate, severe, or life-threatening by incorporating which information set?
4. The 2014 NIH consensus criteria for diagnosing and staging cGVHD delineated signs/symptoms by organ system that:
5. The first agent to be FDA approved for second-line treatment of cGVHD limits pathogenic B-cell expansion by inhibiting:
6. JAK signaling plays an integral role in:
7. Defibrotide, previously approved for hepatic VOD/SOS, is in clinical trials for aGVHD because it has shown efficacy as an:
8. Lee, 58, underwent allo-HSCT for AML. Approximately 4 months later (day 122), he exhibited generalized erythema and bilirubin 6.2 mg/dL. Symptoms worsened after 1 week of high-dose prednisone. What treatment should he receive now?
9. Sarah, 62, underwent allo-HSCT 18 months ago. She had an early episode of aGVHD that resolved with high-dose prednisone. She presented 2 weeks ago with skin and mouth signs that were diagnostic for cGVHD and was placed immediately on high-dose prednisone. This time, however, the steroid isn’t resolving the symptoms. Which treatment approach should be tried now that Sarah seems to be steroid resistant?
10. How confident are you in the management of patients with GvHD in your practice?